Last edition
News about "autoimmune diseases "
Immutep Limited will discontinue the Phase III TACTI-004 trial of eftilagimod alfa in first-line Non-Small Cell Lung Cancer after an interim analysis by the monitoring committee found the study unlikely to meet endpoints.
Autoimmune Diseases | 16/03/2026 | By News Bureau
Antengene Licenses ATG-201 to UCB in Deal Worth Up to USD 1.1 Billion for Autoimmune Disease Therapy
Antengene grants UCB exclusive global rights to develop and commercialise ATG-201, a CD19/CD3 bispecific T-cell engager targeting autoimmune diseases, in a deal worth over USD 1.1 billion in milestones and royalties.
Autoimmune Diseases | 06/03/2026 | By News Bureau | 134
Roche's Fenebrutinib Shows Promise in Third Phase III MS Trial
Roche reported positive Phase III FENhance 1 results, with fenebrutinib reducing relapses by 51 percent in relapsing multiple sclerosis, consistent with prior FENhance 2 and FENtrepid data. The company plans regulatory submissions, positioning fenebrutinib as a potential first-in-class BTK inhibitor for relapsing and primary progressive MS.
Autoimmune Diseases | 02/03/2026 | By News Bureau | 134
Nektar Therapeutics and UCSF collaborate to study TNFR2 agonist NKTR-0165 in multiple sclerosis, aiming to explore its potential for neuroprotection and reduced neurodegeneration.
Autoimmune Diseases | 18/02/2026 | By News Bureau | 130
WuXi Biologics and Vertex Pharmaceuticals collaborate to advance a preclinical trispecific T-cell engager targeting B-cell mediated autoimmune diseases under a global licensing agreement.
Autoimmune Diseases | 03/02/2026 | By News Bureau | 158
IN8bio Prices Private Placement of up to USD 40.2 Million
IN8bio has priced a private placement of up to USD 40.2 million, comprising USD 20.1 million upfront and a milestone-based additional USD 20.1 million, to advance its novel gamma-delta T cell engager INB-619 towards an IND application, extend its cash runway into the first half of 2027.
Autoimmune Diseases | 20/12/2025 | By News Bureau | 140
Innovent's PECONDLE Becomes China's First Approved IL-23p19 Antibody
Innovent has received NMPA approval for PECONDLE (picankibart injection), marking China’s first IL-23p19 monoclonal antibody to be cleared for treating moderate-to-severe plaque psoriasis in adults eligible for systemic therapy.
Autoimmune Diseases | 02/12/2025 | By Dineshwori | 235
US-based biotechnology company Kaigene has signed an exclusive global licensing agreement with South Korean biopharmaceutical giant Celltrion to develop and commercialise two of its nonclinical-stage antibody assets, KG006 and KG002.
Autoimmune Diseases | 04/11/2025 | By Dineshwori | 650
EVOQ Therapeutics Receives USD 2 Million NIH Grant to Develop Therapies for Celiac Disease
The NIH award represents a significant endorsement of EVOQ's ground-breaking approach to harnessing the power of the immune system to treat and prevent autoimmune diseases.
Autoimmune Diseases | 14/10/2025 | By Dineshwori | 233
Bristol Myers Squibb Acquires Orbital Therapeutics
The acquisition of Orbital Therapeutics by Bristol Myers Squibb includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogramme cells in vivo with potential best-in-class profile for autoimmune diseases.
Autoimmune Diseases | 13/10/2025 | By Dineshwori | 225
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy